GC Biopharma Corp. (KRX:006280)

Market Cap	1.60T +11.1%
Revenue (ttm)	1.99T +18.5%
Net Income	-4.67B
EPS	-410.00
Shares Out	11.41M
PE Ratio	n/a
Forward PE	44.72
Dividend	1,500.00 (1.06%)
Ex-Dividend Date	Mar 30, 2026

Volume	46,132
Average Volume	36,898
Open	141,400
Previous Close	141,600
Day's Range	139,800 - 142,000
52-Week Range	117,100 - 183,800
Beta	0.88
RSI	41.20
Earnings Date	Mar 27, 2026

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,042
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 006280

Financial Performance

In 2025, GC Biopharma's revenue was 1.99 trillion, an increase of 18.54% compared to the previous year's 1.68 trillion. Losses were -4.67 billion, -82.22% less than in 2024.